Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials

Background Specific ceramides have been identified as risk markers for cardiovascular disease (CVD) years before onset of disease. Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide has been shown to induce beneficial changes in the lipid profile and reduce the risk of...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Lipids in health and disease Ročník 22; číslo 1; s. 1 - 12
Hlavní autoři:	Wretlind, Asger, Curovic, Viktor Rotbain, de Zawadzki, Andressa, Suvitaival, Tommi, Xu, Jin, Zobel, Emilie Hein, von Scholten, Bernt Johan, Ripa, Rasmus Sejersten, Kjaer, Andreas, Hansen, Tine Willum, Vilsbøll, Tina, Vestergaard, Henrik, Rossing, Peter, Legido-Quigley, Cristina
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 26.09.2023 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Analysis Antidiabetics Biomedical and Life Sciences Calibration Cardiovascular disease Cardiovascular diseases Care and treatment Ceramide Ceramides Cholesterol, LDL Clinical Nutrition Clinical trials Development and progression Diabetes Diabetes mellitus (non-insulin dependent) Dosage and administration Drug therapy Gastrointestinal surgery GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Health aspects Insulin resistance Life Sciences Lipidology Lipids Liquid chromatography Liraglutide Mass spectrometry Mass spectroscopy Measurement Medical Biochemistry Placebos Plasma Precision medicine Scientific imaging Statistical analysis Type 2 diabetes Denmark Type 2 diabetes Ceramide Cardiovascular disease Liraglutide
ISSN:	1476-511X, 1476-511X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!